Abstract

BackgroundAcquired resistance of 5-fluorouracil (5-FU) remains a clinical challenge in colorectal cancer (CRC), and efforts to develop targeted agents to reduce resistance have not yielded success. Metabolic reprogramming is a key cancer hallmark and confers several tumor phenotypes including chemoresistance. Glucose metabolic reprogramming events of 5-FU resistance in CRC has not been evaluated, and whether abnormal glucose metabolism could impart 5-FU resistance in CRC is also poorly defined.MethodsThree separate acquired 5-FU resistance CRC cell line models were generated, and glucose metabolism was assessed by measuring glucose and lactate utilization, RNA and protein expressions of glucose metabolism-related enzymes and changes of intermediate metabolites of glucose metabolite pool. The protein levels of hypoxia inducible factor 1α (HIF-1α) in primary tumors and circulating tumor cells of CRC patients were detected by immunohistochemistry and immunofluorescence. Stable HIF1A knockdown in cell models was established with a lentiviral system. The influence of both HIF1A gene knockdown and pharmacological inhibition on 5-FU resistance in CRC was evaluated in cell models in vivo and in vitro.ResultsThe abnormality of glucose metabolism in 5-FU-resistant CRC were described in detail. The enhanced glycolysis and pentose phosphate pathway in CRC were associated with increased HIF-1α expression. HIF-1α-induced glucose metabolic reprogramming imparted 5-FU resistance in CRC. HIF-1α showed enhanced expression in 5-FU-resistant CRC cell lines and clinical specimens, and increased HIF-1α levels were associated with failure of fluorouracil analog-based chemotherapy in CRC patients and poor survival. Upregulation of HIF-1α in 5-FU-resistant CRC occurred through non-oxygen-dependent mechanisms of reactive oxygen species-mediated activation of PI3K/Akt signaling and aberrant activation of β-catenin in the nucleus. Both HIF-1α gene knock-down and pharmacological inhibition restored the sensitivity of CRC to 5-FU.ConclusionsHIF-1α is a potential biomarker for 5-FU-resistant CRC, and targeting HIF-1a in combination with 5-FU may represent an effective therapeutic strategy in 5-FU-resistant CRC.

Highlights

  • Acquired resistance of 5-fluorouracil (5-FU) remains a clinical challenge in colorectal cancer (CRC), and efforts to develop targeted agents to reduce resistance have not yielded success

  • Establishment and characterization of acquired 5‐FU‐resistant CRC cell lines To investigate the influence of metabolic reprogramming on 5-FU resistance in CRC, we generated three acquired 5-FU resistance (5-FU-R) CRC cell line models (HCT8, HCT15, and LoVo)

  • Similar results were observed with the apoptosis markers Bcl-XL, cleaved caspase 3 and cleaved caspase 9 (Fig. 1f ). These findings indicate that 5-FU-R CRC cells show low response to highdose 5-FU treatment and confirm successful in vitro cell model establishment

Read more

Summary

Introduction

Acquired resistance of 5-fluorouracil (5-FU) remains a clinical challenge in colorectal cancer (CRC), and efforts to develop targeted agents to reduce resistance have not yielded success. Despite recent progress in treatment, the prognosis of CRC remains poor because of the high metastasis and post-intervention recurrence rates [2]. Chemotherapeutic drugs are the main treatment in CRC patients with progression and metastasis, and 5-fluorouracil (5-FU) is a widely used single-agent or key component of systemic chemotherapy for CRC treatment [3, 4]. Drug resistance can emerge after 5-FU treatment. 5-FU pro-drugs and several 5-FU-based combination chemotherapy regimens show beneficial effects, patients with advanced CRC to therapy continue to show poor prognosis due to the development of drug resistance [5]. Elucidation of the underlying 5-FU resistance mechanisms is critical

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call